Seven patients with the mutation p.A53T in the SNCA gene (five PD patients and two asymptomatic carriers) had normal t-Tau and p-Tau CSF levels and marginally decreased Ab1-42 levels in 2 out of the 5 symptomatic carriers [53], not related to the cognitive decline. This evidence concerns the gene MAPT and Parkinson disease.